SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia
Clin Lymphoma Myeloma Leuk. 2023 Jul 26:S2152-2650(23)00230-6. doi: 10.1016/j.clml.2023.07.011. Online ahead of print.ABSTRACTOver the last decade, targeted inhibition of Bruton's tyrosine kinase (BTK) has led to a paradigm shift in the way chronic lymphocytic leukemia (CLL) is managed. BTK inhibitors (BTKi) are broadly classified as covalent BTKI and noncovalent BTKi (cBTKi and ncBTK) Ibrutinib, as the first approved cBTKi, vastly improved outcomes for patients with CLL over prior chemoimmunotherapy regimens. However, long-term use is limited by both intolerance and resistance. The second generation of more selective BTKi...
Source: Clinical Lymphoma and Myeloma - August 6, 2023 Category: Cancer & Oncology Authors: Saumya Easaw Shawyon Ezzati Catherine C Coombs Source Type: research
Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone
CONCLUSION: In this cohort, KRd was not associated with an increase in VTE risk compared to VRd, contrary to prior literature.PMID:37543510 | DOI:10.1016/j.clml.2023.07.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 5, 2023 Category: Cancer & Oncology Authors: Alexa J Loncharich Mark A Fiala Michael J Slade Angela Vickroy Margaret Kavanaugh Carmen Wilson Mark A Schroeder Keith Stockerl-Goldstein Ravi Vij Kristen M Sanfilippo Source Type: research
Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone
CONCLUSION: In this cohort, KRd was not associated with an increase in VTE risk compared to VRd, contrary to prior literature.PMID:37543510 | DOI:10.1016/j.clml.2023.07.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 5, 2023 Category: Cancer & Oncology Authors: Alexa J Loncharich Mark A Fiala Michael J Slade Angela Vickroy Margaret Kavanaugh Carmen Wilson Mark A Schroeder Keith Stockerl-Goldstein Ravi Vij Kristen M Sanfilippo Source Type: research
Multiple Myeloma in Adolescent and Young Adults: An ASCO CancerLinQ and SEER Analysis
CONCLUSION: This analysis highlights some unique characteristics of AYA MM patients in the United States in the modern era.PMID:37541820 | DOI:10.1016/j.clml.2023.07.005 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 4, 2023 Category: Cancer & Oncology Authors: Steven Gibson Jennifer Thornton Kevin Sunderland Kevin Pham Christin DeStefano Source Type: research
Multiple Myeloma in Adolescent and Young Adults: An ASCO CancerLinQ and SEER Analysis
CONCLUSION: This analysis highlights some unique characteristics of AYA MM patients in the United States in the modern era.PMID:37541820 | DOI:10.1016/j.clml.2023.07.005 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 4, 2023 Category: Cancer & Oncology Authors: Steven Gibson Jennifer Thornton Kevin Sunderland Kevin Pham Christin DeStefano Source Type: research
Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of Calgary
Clin Lymphoma Myeloma Leuk. 2023 Jul 17:S2152-2650(23)00213-6. doi: 10.1016/j.clml.2023.07.004. Online ahead of print.NO ABSTRACTPMID:37532664 | DOI:10.1016/j.clml.2023.07.004 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 2, 2023 Category: Cancer & Oncology Authors: Ellen Lewis Sylvia McCulloch Etienne Mahe Nizar Bahlis Paola Neri Jason Tay Peter Duggan Victor H Jimenez-Zepeda Source Type: research
Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of Calgary
Clin Lymphoma Myeloma Leuk. 2023 Jul 17:S2152-2650(23)00213-6. doi: 10.1016/j.clml.2023.07.004. Online ahead of print.NO ABSTRACTPMID:37532664 | DOI:10.1016/j.clml.2023.07.004 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 2, 2023 Category: Cancer & Oncology Authors: Ellen Lewis Sylvia McCulloch Etienne Mahe Nizar Bahlis Paola Neri Jason Tay Peter Duggan Victor H Jimenez-Zepeda Source Type: research
Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study
CONCLUSIONS: RRMM treatments are associated with a high utilization of health care services and pose a significant burden for patients and caregivers.TRIAL REGISTRATION NUMBER: NCT03188536.PMID:37517875 | DOI:10.1016/j.clml.2023.07.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 30, 2023 Category: Cancer & Oncology Authors: Enrique M Ocio Carmen Montes-Gais án Gabriela Bustamante Sebasti án Garzón Esther Gonz ález Ernesto P érez-Persona Ver ónica González-Calle Maialen Sirvent Jos é M Arguiñano Yolanda Gonz ález Rafael R íos Dunia de Miguel Marta Grande Alonso Fer Source Type: research
Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study
CONCLUSIONS: RRMM treatments are associated with a high utilization of health care services and pose a significant burden for patients and caregivers.TRIAL REGISTRATION NUMBER: NCT03188536.PMID:37517875 | DOI:10.1016/j.clml.2023.07.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 30, 2023 Category: Cancer & Oncology Authors: Enrique M Ocio Carmen Montes-Gais án Gabriela Bustamante Sebasti án Garzón Esther Gonz ález Ernesto P érez-Persona Ver ónica González-Calle Maialen Sirvent Jos é M Arguiñano Yolanda Gonz ález Rafael R íos Dunia de Miguel Marta Grande Alonso Fer Source Type: research
Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study
CONCLUSIONS: RRMM treatments are associated with a high utilization of health care services and pose a significant burden for patients and caregivers.TRIAL REGISTRATION NUMBER: NCT03188536.PMID:37517875 | DOI:10.1016/j.clml.2023.07.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 30, 2023 Category: Cancer & Oncology Authors: Enrique M Ocio Carmen Montes-Gais án Gabriela Bustamante Sebasti án Garzón Esther Gonz ález Ernesto P érez-Persona Ver ónica González-Calle Maialen Sirvent Jos é M Arguiñano Yolanda Gonz ález Rafael R íos Dunia de Miguel Marta Grande Alonso Fer Source Type: research
Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma
CONCLUSIONS: The goal of the present review article is to encapsulate these consensus statements and the rationale for their development, which altogether may help inform treatment selection and clinical decision-making in the front line.PMID:37516547 | DOI:10.1016/j.clml.2023.07.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 29, 2023 Category: Cancer & Oncology Authors: Sagar Lonial Andrew D Bowser Ajai Chari Caitlin Costello Amrita Krishnan Saad Z Usmani Source Type: research
Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma
CONCLUSIONS: The goal of the present review article is to encapsulate these consensus statements and the rationale for their development, which altogether may help inform treatment selection and clinical decision-making in the front line.PMID:37516547 | DOI:10.1016/j.clml.2023.07.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 29, 2023 Category: Cancer & Oncology Authors: Sagar Lonial Andrew D Bowser Ajai Chari Caitlin Costello Amrita Krishnan Saad Z Usmani Source Type: research
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
CONCLUSION: The combination of ZO met its primary endpoint of a superior ORR versus O, and demonstrated meaningful activity and a manageable safety profile in patients with R/R FL. ZO had a favorable benefit-risk profile compared with O, and represents a potential combination therapy for patients with R/R FL.PMID:37506346 | DOI:10.1200/JCO.23.00775 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 28, 2023 Category: Cancer & Oncology Authors: Pier Luigi Zinzani Ji ří Mayer Christopher R Flowers Fontanet Bijou Ana C De Oliveira Yuqin Song Qingyuan Zhang Michele Merli Krimo Bouabdallah Peter Ganly Huilai Zhang Roderick Johnson Alejandro Mart ín García-Sancho Mariano Provencio Pulla Marek Trn Source Type: research
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
CONCLUSION: The combination of ZO met its primary endpoint of a superior ORR versus O, and demonstrated meaningful activity and a manageable safety profile in patients with R/R FL. ZO had a favorable benefit-risk profile compared with O, and represents a potential combination therapy for patients with R/R FL.PMID:37506346 | DOI:10.1200/JCO.23.00775 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 28, 2023 Category: Cancer & Oncology Authors: Pier Luigi Zinzani Ji ří Mayer Christopher R Flowers Fontanet Bijou Ana C De Oliveira Yuqin Song Qingyuan Zhang Michele Merli Krimo Bouabdallah Peter Ganly Huilai Zhang Roderick Johnson Alejandro Mart ín García-Sancho Mariano Provencio Pulla Marek Trn Source Type: research
Treatment Individualization in Diffuse Large B-Cell Lymphoma: Is Frailty Enough for Old Adults? An Original Article
CONCLUSIONS: The combination of frailty and physical performance assessment in an algorithm is a promising method to guide the decision-making process in old adults with DLBCL. SPPB might complete frailty predictive information on toxicity risk.PMID:37487908 | DOI:10.1016/j.clml.2023.06.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 24, 2023 Category: Cancer & Oncology Authors: Agurne Garc ía-Baztán Julio Oteiza-Olaso Nancy Jeanette Gonzales-Montejo Maria Fernanda Ram ón-Espinoza Ibai Tamayo-Rodr íguez Nicol ás Martínez-Velilla Mari Cruz Viguria-Alegria Source Type: research
